AVITA Medical Inks Supply Pact With Premier For RECELL System

AVITA Medical Inc RCEL has been awarded a group purchasing agreement with Premier Inc PINC
The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the RECELL System for the treatment of adult and pediatric patients with severe burns.
The RECELL System is a device that enables healthcare professionals to produce a suspension of Spray-On Skin Cells using a small sample of the patient's skin to treat acute thermal burns.
This new agreement enables AVITA Medical access to Premier's member hospitals and regional representatives to help facilitate the adoption of the RECELL System into their facilities.
Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 225,000 other providers.
Last month, the FDA approved the premarket approval application supplement for RECELL Autologous Cell Harvesting Device, an enhanced RECELL System that provides clinicians with a more efficient user experience and simplified workflow.
The launch of the new RECELL System in the United States will begin in Q2 2022.
Price Action: RCEL shares are up 5.22% at $10.48 on the last check Thursday.

Overview Rating:

Good

0100